PNS143 PREFERENCES IN THE PRESCRIPTION OF INSULINS IN PATIENTS WITH TYPE II DIABETES MELLITUS IN COLOMBIA

Abstract

To compare the preferences in the prescription of insulin initiation in patients with Type II Diabetes Mellitus. Through a consumption database of approximately 65 million records of II semester of 2015 and I semester of 2016 in a Colombian insurer, 730 patients were identified who had de novo insulin use (NPH - Degludec - Glargina - Detemir) and diagnosis confirmed with type II diabetes mellitus. From this population, patients who had combination therapies in the same period were excluded and the other patients were classified by trimesters according to the period of treatment initiation; decreasing the database to 526 patients (165 - III quarter of 2015, 136 - IV of quarter 2015, 114 - I quarter of 2016 and 111 – II quarter of 2016), who were monitored for insulin consumption for 18 months. The treatments were classified into modern therapies and therapy with NPH. At the beginning of treatment, patients with modern therapies and therapy with NPH were distributed as follows: in the III quarter of 2015 (51.5%, 48.5%), IV quarter of 2015 (45.6%, 54.4%), I quarter of 2016 (62.3%, 37.7%) and II quarter of 2016 (72.1%, 27.9%), respectively for modern therapies and therapy with NPH. At 18 months, 43% of the patients who started with modern therapies and 78.9% of the patients who started with NPH therapy had changed their treatment. The prescription of modern therapies in the beginning of the treatment is preferred over the therapy with NPH, increasing the preference as time passes. Patients who start with modern therapies are more stable in their treatment than patients who start with NPH therapy.